Datavant, a leading health data platform company, today announced the successful completion of its acquisition of Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. Aetion is now part of Datavant’s Life Sciences business.

"This transaction represents the beginning of a promising new chapter together for two industry-leaders whose joint mission is to make real world evidence truly actionable, and we are delighted to welcome the Aetion team to Datavant,” said Kyle Armbrester, CEO of Datavant.

With the completion of this acquisition, Datavant is well-positioned to deliver an end-to-end platform for data feasibility and analysis, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market.

“We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum,” Armbrester added.

Datavant and Aetion have a combined ecosystem of over 300 data partners comprising datasets and insights across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more.

About Datavant

Datavant is a health data platform company. We make the world’s health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit datavant.com and follow us on LinkedIn.

About Aetion

Aetion®, a Datavant company, is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion’s investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at aetion.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250711641995/en/

We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum.